文拉法辛治疗广泛性焦虑症的临床疗效分析

摘要

目的：探讨分析文拉法辛治疗广泛性焦虑症的临床疗效和不良反应。方法本实验选择2012年6月至2013年3月份在我院治疗广泛性焦虑症的患者134例为研究对象，随机分为2组，观察组（文拉法辛治疗组）66例，对照组（阿普唑仑治疗组）68例，分析两组广泛性焦虑症患者治疗效果及不良反应。结果观察组治疗前 SAS 及 HAMA 评分以及治疗后 SAS 及 HAMA 评分分与对照组比较差异不明显；观察组治愈率为43.9%，与对照组比较差异不明显，以上均P>0.05。不良反应发生率观察组发生率为18.2%，明显低于对照组，差异明显，P<0.05。结论文拉法辛对于广泛性焦虑症的治疗安全有效，且不良反应少。%Objective To discuss the clinical curative effect and adverse reactions of venlafaxine for the treatment of generalized anxiety. Methods From June, 2012 to March, 2013, 134 patients with generalized anxiety were selected as the research objects in our hospital. They were randomly divided into observation group (venlafaxine group, n=66) and control group (alprazolam group, n=68), the clinical curative effect and adverse reactions were analyzed for the patients with generalized anxiety in two groups. Results In observation group, SAS and HAMA scores were compared before and after the treatment, there were no obvious differences when compared with the control group; In observation group, the cure rate was 43.9%, the differences were not obvious when compared with the control group, above P>0.05. The incidence of adverse reactions was 18.2%, it was significantly lower than the control group, the difference was significant,P<0.05. Conclusion Venlafaxine is safe and effective for the treatment of generalized anxiety, the adverse reactions are less.